FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2776609079> ?p ?o ?g. }

• W2776609079 endingPage "1168" @default.
• W2776609079 startingPage "1160" @default.
• W2776609079 abstract "BACKGROUND The achievement of a sustained deep molecular response is a goal of increasing relevance because it opens the possibility of treatment discontinuation. The objective of this analysis was to develop a prediction model for a sustained molecular response with BCR‐ABL1 level <0.0032% on the international scale (MR 4.5 ) for at least 2 years according to BCR‐ABL1 levels achieved within the first 12 months of therapy. METHODS Data for 603 patients with newly diagnosed chronic myeloid leukemia in chronic phase in consecutive prospective clinical trials were analyzed. The best fit average molecular response was defined by robust linear regression models, with which the average molecular levels were defined. The minimum acceptable molecular response was defined by quantile regression for the 95th percentile, with which the worst 5% BCR‐ABL1 levels were identified. RESULTS In 603 patients with a median follow‐up of 103 months, 2002 BCR‐ABL1 –level data points within 1 year of tyrosine kinase inhibitors were identified. The regression equation for the best fit average levels for a sustained MR 4.5 was Log 10 (PCR) = −0.1424 × (Months) – 0.8668, and the regression equation for minimum acceptable levels was Log 10 (PCR) = −0.1403 × (Months) + 0.6142 (where PCR indicates polymerase chain reaction). To achieve a sustained MR 4.5 , the best fit average levels were 0.051%, 0.019%, 0.007%, and 0.003% at 3, 6, 9, and 12 months, respectively; the minimum acceptable levels were 1.561%, 0.592%, 0.225%, and 0.085% at 3, 6, 9, and 12 months, respectively. CONCLUSIONS This model proposes optimal values that predict the highest probability of reaching such a goal. These values can be used to guide therapy when a sustained MR 4.5 is the objective. Cancer 2018;124:1160‐8 . © 2017 American Cancer Society ." @default.
• W2776609079 created "2018-01-05" @default.
• W2776609079 creator A5000750846 @default.
• W2776609079 creator A5011548707 @default.
• W2776609079 creator A5015140142 @default.
• W2776609079 creator A5022647201 @default.
• W2776609079 creator A5028845635 @default.
• W2776609079 creator A5029750735 @default.
• W2776609079 creator A5030500582 @default.
• W2776609079 creator A5035605515 @default.
• W2776609079 creator A5051949215 @default.
• W2776609079 creator A5055045706 @default.
• W2776609079 creator A5057701424 @default.
• W2776609079 creator A5061026876 @default.
• W2776609079 creator A5085419504 @default.
• W2776609079 creator A5089428686 @default.
• W2776609079 creator A5090435894 @default.
• W2776609079 date "2017-12-20" @default.
• W2776609079 modified "2023-10-18" @default.
• W2776609079 title "Prediction for sustained deep molecular response of<i>BCR-ABL1</i>levels in patients with chronic myeloid leukemia in chronic phase" @default.
• W2776609079 cites W1814874339 @default.
• W2776609079 cites W1966006461 @default.
• W2776609079 cites W1968747503 @default.
• W2776609079 cites W2001335864 @default.
• W2776609079 cites W2013428225 @default.
• W2776609079 cites W2052923507 @default.
• W2776609079 cites W2057206328 @default.
• W2776609079 cites W2064367288 @default.
• W2776609079 cites W2068977368 @default.
• W2776609079 cites W2075193502 @default.
• W2776609079 cites W2085342571 @default.
• W2776609079 cites W2107268345 @default.
• W2776609079 cites W2117356576 @default.
• W2776609079 cites W2135620625 @default.
• W2776609079 cites W2146658081 @default.
• W2776609079 cites W2147109509 @default.
• W2776609079 cites W2157330275 @default.
• W2776609079 cites W2157436488 @default.
• W2776609079 cites W2166654361 @default.
• W2776609079 cites W2167325977 @default.
• W2776609079 cites W2168633862 @default.
• W2776609079 cites W2172189430 @default.
• W2776609079 cites W2189113171 @default.
• W2776609079 cites W2260921597 @default.
• W2776609079 cites W2397234997 @default.
• W2776609079 cites W2483445141 @default.
• W2776609079 cites W2588916936 @default.
• W2776609079 doi "https://doi.org/10.1002/cncr.31187" @default.
• W2776609079 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5851790" @default.
• W2776609079 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29266206" @default.
• W2776609079 hasPublicationYear "2017" @default.
• W2776609079 type Work @default.
• W2776609079 sameAs 2776609079 @default.
• W2776609079 citedByCount "22" @default.
• W2776609079 countsByYear W27766090792018 @default.
• W2776609079 countsByYear W27766090792019 @default.
• W2776609079 countsByYear W27766090792020 @default.
• W2776609079 countsByYear W27766090792021 @default.
• W2776609079 countsByYear W27766090792022 @default.
• W2776609079 countsByYear W27766090792023 @default.
• W2776609079 crossrefType "journal-article" @default.
• W2776609079 hasAuthorship W2776609079A5000750846 @default.
• W2776609079 hasAuthorship W2776609079A5011548707 @default.
• W2776609079 hasAuthorship W2776609079A5015140142 @default.
• W2776609079 hasAuthorship W2776609079A5022647201 @default.
• W2776609079 hasAuthorship W2776609079A5028845635 @default.
• W2776609079 hasAuthorship W2776609079A5029750735 @default.
• W2776609079 hasAuthorship W2776609079A5030500582 @default.
• W2776609079 hasAuthorship W2776609079A5035605515 @default.
• W2776609079 hasAuthorship W2776609079A5051949215 @default.
• W2776609079 hasAuthorship W2776609079A5055045706 @default.
• W2776609079 hasAuthorship W2776609079A5057701424 @default.
• W2776609079 hasAuthorship W2776609079A5061026876 @default.
• W2776609079 hasAuthorship W2776609079A5085419504 @default.
• W2776609079 hasAuthorship W2776609079A5089428686 @default.
• W2776609079 hasAuthorship W2776609079A5090435894 @default.
• W2776609079 hasBestOaLocation W27766090791 @default.
• W2776609079 hasConcept C104317684 @default.
• W2776609079 hasConcept C105795698 @default.
• W2776609079 hasConcept C122048520 @default.
• W2776609079 hasConcept C126322002 @default.
• W2776609079 hasConcept C143998085 @default.
• W2776609079 hasConcept C2778715236 @default.
• W2776609079 hasConcept C2778729363 @default.
• W2776609079 hasConcept C33923547 @default.
• W2776609079 hasConcept C48126324 @default.
• W2776609079 hasConcept C48921125 @default.
• W2776609079 hasConcept C49105822 @default.
• W2776609079 hasConcept C54355233 @default.
• W2776609079 hasConcept C63817138 @default.
• W2776609079 hasConcept C71924100 @default.
• W2776609079 hasConcept C86803240 @default.
• W2776609079 hasConcept C90924648 @default.
• W2776609079 hasConceptScore W2776609079C104317684 @default.
• W2776609079 hasConceptScore W2776609079C105795698 @default.
• W2776609079 hasConceptScore W2776609079C122048520 @default.
• W2776609079 hasConceptScore W2776609079C126322002 @default.
• W2776609079 hasConceptScore W2776609079C143998085 @default.

• next